Oruka Therapeutics
ORKA
42 hedge funds and large institutions have $604M invested in Oruka Therapeutics in 2024 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 12 closing their positions.
1,122% more capital invested
Capital invested by funds: $49.4M → $604M (+$555M)
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
208% more call options, than puts
Call options by funds: $453K | Put options by funds: $147K
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
62.75% more ownership
Funds ownership: 7.42% → 70.17% (+63%)
35% more funds holding
Funds holding: 31 → 42 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$163M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$112M |
| 3 |
VA
VR Adviser
New York
|
+$105M |
| 4 |
RI
RTW Investments
New York
|
+$60.3M |
| 5 |
CC
Commodore Capital
New York
|
+$46.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$280K |
| 2 |
State Street
Boston,
Massachusetts
|
-$229K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$163K |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$124K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$106K |
ORKA Hedge Fund Activity: Q3 2024 in Review
42 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2024, worth a combined $604M — up 1,122% from $49.4M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ORKA positions and 12 closed out — a net gain of 11 holders — while 14 added to existing stakes and 3 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $163M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $280K sold.
- 42 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2024, up from 31 in Q2 2024.
- Funds reported $604M of Oruka Therapeutics stock for Q3 2024, up 1,122% quarter-over-quarter.
- 23 funds opened new Oruka Therapeutics positions in Q3 2024 and 12 closed out, a net change of +11 holders.
- The largest Oruka Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $163M added.
- The largest Oruka Therapeutics seller in Q3 2024 was Renaissance Technologies, an estimated $280K sold.
Based on aggregated 13F filings for Q3 2024.